NCT04630730
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 19 versions: 16 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 25 words
- Primary completion date changed from estimate of Jun 2026 to Apr 26, 2026
- Secondary endpoints: details revised at 10 of 10 entries
- Publications: details revised at 1 of 1 entry
- Minor Site details revised at 1 of 10 sitesv18
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 10 of 10 sites
- Notable Enrollment target: 5 to 46v15
- Notable Trial status: Active, Not Recruiting to Recruiting
- Site details revised at 10 of 10 sites
Show 10 earlier versionsHide 10 earlier versions
- Notable Trial status: Suspended to Active, Not Recruiting
- Eligibility criteria expanded, about 21 words
- Enrollment target: estimated 46 to confirmed 5
- Stopped Trial status: Active, Not Recruiting to Suspended Sponsor's reason: temporarily suspended for accrual due to "out of specification" notification for IMP batch.v11
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 10 of 10 sites
- Minor Site contacts updated at 1 of 10 sitesv9
- Minor Study sites: 9 to 10v8
- Minor Start date changed from estimate of May 2022 to Jun 24, 2022v7
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Jul 2022 to May 2022
- Site details revised at 9 of 9 sites
- Notable Start date: Dec 2021 to Jul 2022v4
Notable Primary completion date: Sep 2025 to Jun 2026v3 Show 6 more changesShow less
- Start date: Jul 2021 to Dec 2021
- Eligibility criteria shortened, about 2 words
- Enrollment target: 62 to 46
- Study sites: 6 to 9
- Study completion date: Sep 2029 to Jun 2030
- Secondary endpoints: details revised at 1 of 10 entries
- Notable Primary completion date: Feb 2025 to Sep 2025
- Start date: Feb 2021 to Jul 2021
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (10)
Show 5 moreShow less
Arms and interventions
The Intravesical recombinant BCG (Bacillus Calmette-Guérin - VPM1002BC) is used as an immuno-stimulating agent. The patient will receive 3 weekly BCG instillations as induction treatment. 4 cycles of atezolizumab, a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1 inhibitor) will be administered in combination with the standard neoadjuvant chemotherapy cisplatin/gemcitabine. After surgery atezolizumab will be administered in the adjuvant setting for 13 cycles.
Drugs: Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC), Atezolizumab, Cisplatin, Gemcitabine
Sites
10 sites in 1 country